Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Blinded Endpoint, Multi-center, Cross-over Study to Evaluate the Effect of High and Low Sodium Diets on Reduction in Mean 24-hour Ambulatory Blood Pressure in Systolic Hypertensive Patients Treated With Aliskiren (300 mg)

NCT00441064 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00441064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00441064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Blinded Endpoint, Multi-center, Cross-over Study to Evaluate the Effect of High and Low Sodium Diets on Reduction in Mean 24-hour Ambulatory Blood Pressure in Systolic Hypertensive Patients Treated With Aliskiren (300 mg)
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2007
Completion date
November 30, 2007
Enrollment
132 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension